3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
20
NIH
3
NETWORK
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Myelodysplastic Syndromes
2
Melanoma
2
Leukemia, Promyelocytic, Acute
2
Leukemia
2
Hematologic Neoplasms
2
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Neoplasms
1
Hematologic Diseases
1
Interventions
Arsenic Trioxide
4
Tretinoin
2
vadastuximab talirine
1
tamibarotene
1
cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV))
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Cytarabine
1
Clofarabine
1
AEG 35156
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Promyelocytic, Acute
×
Tretinoin
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled
NCT07296445
2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3
Not yet recruiting
120 enrolled